Twist Bioscience Corporation (NASDAQ:TWST), a player in the U.S. Life Science Tools & Diagnostics sector, has been making strides in operational efficiency and product development. This ...

Twist Bioscience retains a 24% equity interest in Atlas and will benefit from royalties, milestone payments, and technology advancements. Revenue reached $92.8 million, showing a year-over-year ...

Twist Bioscience (NASDAQ:TWST) is gearing up to announce its quarterly earnings on Monday, 2025-05-05. Here's a quick overview of what investors should know before the release. Analysts are ...

Twist Bioscience's second quarter results were strong, driven by NGS demand, and the company expects this strength to continue. Twist's valuation probably limits near-term upside, but the company ...

As Twist Bioscience aims to untangle its operations and focus only on its most potentially profitable work, the synthetic DNA maker is cutting down its workforce. In an earnings report released ...

Twist Bioscience reported revenue of $81.5 million in Q2 (fiscal Q3), marking a 28% increase from Q2, 2023. Twist's biopharma segment underperformed, contributing to a significant impairment charge.

Twist Bioscience (TWST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steven Mah from TD Cowen maintained a Buy rating on the stock and ...

A downtrend has been apparent in Twist Bioscience (TWST) lately. While the stock has lost 9.9% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its ...

Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “For customers running large scale population studies, validating genetic biomarkers or screening target therapeutics, our industry ...